Virulent and attenuated mutant Venezuelan equine encephalitis virus show marked differences in replication in infection in murine macrophages

Microbial Pathogenesis

Volumn 21, Issue 2, 1996, Pages 85-95

  Grieder, Franziska B ^a   Nguyen, Hanh T ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

interferon ; lipopolysaccharide; macrophage; murine; Venezuelan equine encephalitis virus

Indexed keywords

ANIMAL CELL; ANTIBODY TITER; ARTICLE; ATTENUATION; IMMUNOPEROXIDASE STAINING; MACROPHAGE ACTIVATION; MOLECULAR CLONING; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; STRAIN DIFFERENCE; TARGET CELL; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS MUTANT; VIRUS REPLICATION; VIRUS VIRULENCE;

ALPHAVIRUS; ANIMALIA; EQUIDAE; MURINAE; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

EID: 0030218898     PISSN: 08824010     EISSN: None     Source Type: Journal    
DOI: 10.1006/mpat.1996.0045     Document Type: Article

References (35)

1. 1. Henke A, Spenger H-P, Stelzer A, Nain M, Gemsa D. Lipopolysaccharide suppresses cytokine release from coxsackie virus-infected human monocytes. Res Immunol 1992; 143: 65-70.
2. 2. Metzler MS, Gendelman HE. Mononuclear phagocytes as targets, tissue reservoirs, and immunoregulatory cells in human immunodeficiency virus disease. Curr Top Microbiol Immunol 1992; 18: 239-263.
3. 3. Becker S, Quay J, Soukup J. Cytokine (Tumor necrosis factor, IL-6, and IL-8) production by Respiratory syncytial virus-infected human alveolar macrophages. J Immun 1991; 147: 4307-4312.
4. 4. Gong JH, Sprenger H, Hinder F, Bender A, Schmidt A, Horch S, Nain M, Gemsa D. Influenza A virus infection of macrophages - enhanced tumor necrosis factor-α (TNF-α) gene expression and lipopolysaccharide-triggered TNF-a release. J Immunol 1991; 147: 3507-3513.
5. 5. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986; 233: 215-219.
6. 6. Mosier D, Sieburg H. Macrophage-tropic HIV: critical for AIDS pathogenesis? Immunol Today 1994; 15: 332-339.
7. 7. Bulrinsky MI, Nottet HS, Schmidtmayerova H, Dubrovsky L, Flanagan CR, Mulline ME, Lipton SA, Gendelman HE. Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-induced monocytes: implications for HIV-associated neurological disease. J Exp Med 1995; 181: 738-745.
8. 8. Fingerote RJ, Cruz BM, Gorczynski RM, Fung LS, Hubbell HR, Suhadolnik RJ, Levy GA. A 2′,5′-oligoadenylate analogue inhibits murine hepatitis virus strain 3 (MHV-3) replication in vitro but does not reduce MHV-3-related mortality of induction of procoagulant activity in susceptible mice. J Gen Virol 1995; 76: 373-380.
9. 9. Iwamoto GK, Konicek SA, Twigg HL. Modulation of accessory cell function and interleukin-6 production by the HIV1 tat gene. Am J Resp Cell Mol Biol 1994; 10: 580-585.
10. 10. Saville MW, Taga K, Foli A, Broder S, Tosato G, Yarchoan R. Interleukine-10 suppresses human immunodeficiency virus-1 replication in vitro cells of the monocyte/macrophage lineage. Blood 1994; 83: 3591-3599.
11. 11. Cohn Z. The activation of mononuclear phagocytes: Fact, fancy, and future. J Immunol 1978; 121: 813-816.
12. 12. Gleiser CA, Gochenour WS, Berge TO, Tigertt WD. The comparative pathology of experimental Venezuelan equine encephalomyelitis infection in different animal hosts. J Inf Dis 1962; 98: 55-66.
13. 13. Tasker JB, Miesse ML, Berge TO. Studies on the virus of Venezuelan equine encephalitis. III. Distribution in tissue of experimentally infected mice. Am J Trop Med Hyg 1962; 11: 844-850.
14. 14. Victor J, Smith DG, Pollack AD. The comparative pathology of Venezuelan equine encephalitis. J Inf Dis 1956; 98: 55-66.
15. 15. Johnson BJB, Kinney RM, Kost CL, Trent DW. Molecular determinants of alphavirus virulence: nucleotide and deduced protein sequence changes during attenuation of Venezuelan equine encephalitis virus. J Gen Virol 1986; 67: 1951-1960.
16. 16. Grieder FB, Davis NL, Aronson JF, Charles PC, Sellon DC, Suzuki K, Johnston RE. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology 1995; 206: 994-1006.
17. 17. Davis NL, Willis LV, Smith JF, Johnston RE. In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology 1989; 171: 189-204.
18. 2 glycoprotein gene of Venezuelan equine encephalitis virus: Construction of single and multiple mutants in a full-length cDNA clone. Virology 1991; 18: 20-31.
19. 19. Davis NL, Grieder FB, Smith JF, Greenwald GF, Valenski ML, Sellan DC, Charles PC, Johnston RE. A molecular genetic approch to the study of Venezuelan equine encephalitis virus pathogenesis. Arch Virol 1994; 9: 99-109.
20. 20. Scherer WF, Ellsworth CD, Ventura AK. Studies of viral virulence. II. Growth and adsorption curves of virulent and attenuated strains of Venezuelan encephalitis virus in cultured cells. Am J Path 1971; 62: 211-219.
21. 21. Kinney RM, Johnson BJB, Welch JB, Tsuchiya KR, Trent DW. The full-length sequence of the virulent Trinidad Donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccin derivative, strain TC-83. Virol 1989; 170: 19-30.
22. 22. Johnston RE, Smith JF. Selection for accelerated penetration in cell culture coselects for attenuated mutants of Venezuelan equine encephalitis virus. Virol 1988; 162: 437-443.
23. 23. Roehrig JT, Hunt AR, Kinney RM, Matthews JH. In vitro mechanisms of monoclonal antibody neutralization of alphaviruses. Virology 1988; 165: 66-73.
24. 24. Hunt AR, Johnson AJ, Roehrig JT. Synthetic peptides of Venezuelan equine encephalitis virus E2 glycoprotein. I. Immunogeneic analysis and identification of a protective peptide. Virology 1990; 179: 701-711.
25. 25. Tsai W-P, Hirose K, Nara PL, Kuang Y-D, Conley S, Li B-Q, Kung H-F, Matsushima K. Decrease in cytokine production by HIV-infected macrophages in response to LPS-mediated activation. Lymphokine Cytokine Res 1991; 10: 421-429.
26. 26. Peschke T, Bender A, Nain M, Gemsa D. Role of macrophages in influenza A virus infection. Immunobiol 1993; 189: 340-355.
27. 27. Temonen M, Lankinen H, Vapalahti O, Ronni T, Julkunen I, Vaheri A. Effect of interferon-α and cell differentiation on Puumala virus infection in human monocyte/macrophages. Virology 1995; 206: 8-15.
28. 28. Poli G, Fauci AS. The role of monocytes/macrophages and cytokines in the pathogenesis of HIV infection. Pathobiology 1992; 60: 245-251.
29. 29. Kornbluth RS, Oh PS, Munis PH, Cleveland PH, Richmann DD. The role of interferons in the control of HIV replication in macrophages. Clin Immunol Immunopathol 1990; 54: 200-207.
30. 30. Valentin A, Albert J, Svenson SB, Asjo B. Blood-derived macrophages produce IL-1, but not TNF-a, after infection with HIV-1 isolates from patients at different stages of disease. Cytokine 1992; 4: 185-191.
31. 31. Poli G, Kinter AL, Justement JS, Bressler P, Kehrl JH, Fauci AS. Transforming growth factor b suppresses human immunodeficiency virus expression and replication in infected cells of the monocyte/macrophage lineage. J Exp Med 1991; 173: 589-596.
32. 32. Mellors JW, Griffith BP, Oritz MA, Landry ML, Ryan JL. Tumor necrosis factor-α/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages. J Inf Dis 1990; 163: 78-82.
33. 33. Duc Dodon M, Vogel SN. Analysis of lipopolysaccharide and interferon on murine macrophages: modulation of elastase secretion in vitro. Infect Immun 1985; 49: 709-714.
34. 34. Gordon S, Todd J, Cohn ZA. In vitro synthesiss and secretion of lysozyme by mononuclear phagocytes. J Exp Med 1974; 139: 1228-1246.
35. 35. McIntire FC, Sievert HW, Barlow GH, Finley RA, Lee AY. Chemical, physical, and biological properties of a lipopolysaccharide from Escherichia coli K-235. Biochemistry 1967; 6: 2363-2372.